

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

### Sulfoglycolipid from the Marine Brown Alga *Sargassum Hemiphyllum*

Zheng Cui; Yu-Shan Li<sup>a</sup>; Hong-Bing Liu<sup>a</sup>; Dan Yuan<sup>a</sup>; Bao-Ren Lu<sup>b</sup>

<sup>a</sup> Shenyang Pharmaceutical University, Shenyang, China <sup>b</sup> Institute of Marine, Chinese Academy of Sciences, Qingdao, China

**To cite this Article** Cui, Zheng , Li, Yu-Shan , Liu, Hong-Bing , Yuan, Dan and Lu, Bao-Ren(2001) 'Sulfoglycolipid from the Marine Brown Alga *Sargassum Hemiphyllum*', *Journal of Asian Natural Products Research*, 3: 2, 117 – 122

**To link to this Article:** DOI: 10.1080/10286020108041378

**URL:** <http://dx.doi.org/10.1080/10286020108041378>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SULFOGLYCOLIPID FROM THE MARINE BROWN ALGA *SARGASSUM HEMIPHYLLUM*

ZHENG CUI<sup>a,\*</sup>, YU-SHAN LI<sup>a</sup>, HONG-BING LIU<sup>a</sup>,  
DAN YUAN<sup>a</sup> and BAO-REN LU<sup>b</sup>

<sup>a</sup>Shenyang Pharmaceutical University, 103 Wen Hua Street, Shenyang 110015, China;

<sup>b</sup>Institute of Marine, Chinese Academy of Sciences, Qingdao 266071, China

(Received 6 September 1999; In final form 3 May 2000)

One kinds of glycolipid (SBI) have been isolated from the marine brown alga *Sargassum hemiphyllum* (Turn.) Ag. The structures of SBI have been determined as the sodium salt of 1-0-acyl-3-0-(6'-sulfo- $\alpha$ -D-quinovopyrannosyl) glycerol (acyl: tetradecanoyl, pentadecanoyl, 11-hexadecenoyl, hexadecanoyl, 10,13-octadecadienoyl, 9-octadecenoyl, 15-methylheptadecanoyl and 11-eicosenoyl 17:1.5:19:153:1:19:1:2) on the basis of chemical and spectral evidence and GC-MS analysis, respectively. Four constituents of the SBI were new compounds [the sodium salt of 1-0-(11''-hexadecenoyl)-3-0-(6'-sulfo- $\alpha$ -D-quinovopyrannosyl) glycerol, the sodium salt of 1-0-(10'',13''-octadecadienoyl)-3-0-(6'-sulfo- $\alpha$ -D-quinovopyrannosyl) glycerol, and the sodium salt of 1-0-(15''-methylhexadecenoyl)-3-0-(6'-sulfo- $\alpha$ -D-quinovopyrannosyl) glycerol, and the sodium salt of 1-0-(11''-eicosenoyl)-3-0-(6'-sulfo- $\alpha$ -D-quinovopyrannosyl) glycerol]. All compounds were isolated from marine brown alga for the first time.

**Keywords:** Marine; Brown alga; *Sargassum hemiphyllum*; Sulfonoglycolipid

### INTRODUCTION

*Sargassum hemiphyllum* (Turn.) Ag. is native to Eastsea and Southsea of China. The alga is used in Chinese folk medicine for the treatment of goiter, tumor, scrofula painful, swollen testis and edema due to the retention of phlegm [1]. In a preliminary investigation the *n*-butanolic extract of the alga exhibited anti-cancer activities in mouse S<sub>180</sub> tumor model (0.19 g/kg) [2]. During the course of our investigation on marine natural products, we have

\*Corresponding author. Tel.: 86 24 23843711-3523, Fax: 86 24 83890024, e-mail: cuizphd@mail.sy.cn



TABLE 1  $^{13}\text{C}$  NMR Data for SBI(1), 2\_and 3 (in  $\text{CD}_3\text{OD}$ )

Carbon	1	2	3
1'	100.1 (d)	100.2 (d)	99.2 (d)
2'	73.4 (d)	73.5 (d)	72.2 (d)
3'	75.0 (d)	75.0 (d)	73.9 (d)
4'	74.7 (d)	75.0 (d)	73.4 (d)
5'	69.7 (d)	69.8 (d)	69.1 (d)
6'	54.1 (t)	54.4 (t)	53.1 (t)
1	66.5 (t)	64.4 (t)	63.7 (t)
2	70.4 (d)	71.8 (d)	71.7 (d)
3	69.7 (t)	67.3 (t)	69.8 (t)

The sulfonoglycoside was determined as 6'-sulfo-0- $\alpha$ -quinovopyranosyl-(1'→3)-glycerol by comparison of the  $^{13}\text{C}$ -NMR data of 3 from a marine sponge [7]. The mixture of fatty acid methyl esters was subjected to GC-MS for identification (Fig. 2). The fatty acid compositions in 1 were shown to be methyl tetradecanoate [242( $\text{M}^+$ ), 211, 74]; methyl pentadecanoate [256( $\text{M}^+$ ), 225, 74]; methyl 11-hexadecenoate [268 ( $\text{M}^+$ ), 236, 208 ( $\text{C}_{15}\text{H}_{28}$ ) $^+$ , 194 ( $\text{C}_{14}\text{H}_{26}$ ) $^+$ , 152 ( $\text{C}_{11}\text{H}_{20}$ ) $^+$ , 83 ( $\text{C}_6\text{H}_{11}$ ) $^+$ , 74, 69 ( $\text{C}_5\text{H}_9$ ) $^+$ ]; methyl hexadecanoate [270 ( $\text{M}^+$ ), 239, 185, 74]; methyl 10,13-octadecadienoate [294( $\text{M}^+$ ), 263, 124 ( $\text{C}_9\text{H}_{16}$ ) $^+$ , 81 ( $\text{C}_6\text{H}_9$ ) $^+$ , 67 ( $\text{C}_5\text{H}_7$ ) $^+$ ]; methyl 9-octadecenoate [296( $\text{M}^+$ ), 264 ( $\text{C}_{18}\text{H}_{32}\text{O}$ ) $^+$ , 222 ( $\text{C}_{16}\text{H}_{30}$ ) $^+$ , 166 ( $\text{C}_{12}\text{H}_{22}$ ) $^+$ , 152 ( $\text{C}_{11}\text{H}_{20}$ ) $^+$ , 74]; methyl 15-methylheptadecanoate [298 ( $\text{M}^+$ ), 267 ( $\text{C}_{18}\text{H}_{35}\text{O}$ ) $^+$ , 255, 199 ( $\text{C}_{12}\text{H}_{23}\text{O}_2$ ) $^+$ , 143 ( $\text{C}_8\text{H}_{15}\text{O}$ ) $^+$ , 129 ( $\text{C}_7\text{H}_{13}\text{O}$ ) $^+$ , 74]




FIGURE 2 The GC-MS analysis of SBI (1).

and methyl 11-eicosenoate [324 (M)<sup>+</sup>, 292, 250 (C<sub>18</sub>H<sub>34</sub>)<sup>+</sup>, 208 (C<sub>15</sub>H<sub>28</sub>)<sup>+</sup>, 152 (C<sub>11</sub>H<sub>20</sub>)<sup>-</sup>, 137 (C<sub>10</sub>H<sub>18</sub>)<sup>+</sup>, 123 (C<sub>9</sub>H<sub>15</sub>)<sup>+</sup>, 74] (17:1.5:19:153:1:19:1:2). Consequently, the chemical structure of **1** was determined as the sodium salt of 1-0-acyl-3-0-(6'-sulfo- $\alpha$ -D-quinovopyrannosyl) glycerol (acyl: tetradecanoyl, pentadecanoyl, 11-hexadecenoyl, hexadecanoyl, 10, 13-octadecadienoyl, 9-octadecenoyl, 15-methyl heptadecanoyl, 11-eicosenoyl).

It is interesting to note that a 6'-sulfoquinovosyl glyceride, a substance closely related to SBI from the blue alga, could restrain the copy of HIV. It was a new kind of substance having anti-HIV activity [8].

## EXPERIMENTAL SECTION

### General Experimental Procedures

The IR spectra were recorded on a Bruker IFS-55 spectrometer. The <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra were run on a Bruker AC-250 and a Bruker AC (X)-300 spectrometer. The FABMS were taken on a JNS-D 300 mass spectrometer, EIMS on a DX-300 mass spectrometer. The GC-MS was taken on a VG700 mass spectrometer. Separation and purification were performed by column chromatography on silica gel (300–400 and 180–200 mesh) and Sephadex LH-20.

### Plant Material

The *Sargassum hemiphyllum* (Turn.) Ag. were collected in July, 1992 from Naozhou, Guangdong Province, China. The sample was provided and identified by Prof. LU, Qingdao Institute of Marine, Chinese Academy of Sciences, China. The sample has been deposited in Traditional Chinese Medicine Department of Shenyang Pharmaceutical University.

### Extraction and Isolation

Air-dried finely cut alga (1.8 kg) was successively extracted with petroleum ether, EtOAc and MeOH at room temperature. The methanol extract was then partitioned into *n*-BuOH-H<sub>2</sub>O to give the *n*-BuOH extract (8 g). This extract was fractionated by vacuum liquid chromatography over silica gel developing with EtOAc–MeOH (20:1→1:1) to furnish two fractions FrII and FrV. The FrV was subjected to column chromatography over silica gel (CHCl<sub>3</sub>–MeOH–H<sub>2</sub>O 10:3:1) and Sephadex LH-20 (CHCl<sub>3</sub>–MeOH 1:1) to afford SBI (30 mg).

**SBI (1)**

White amorphous powder; IR(KBr)  $\nu_{\max}$  3428, 1733, 1462, 1172, 1033  $\text{cm}^{-1}$ ; FDMS  $m/z$ : 601 (M+Na)<sup>+</sup>, 627 (M+Na)<sup>+</sup>, 655 (M+Na)<sup>+</sup>. EIMS  $m/z$ : 550 (M<sup>+</sup>), 576 (M<sup>+</sup>). <sup>1</sup>H-NMR (<sup>1</sup>H-<sup>1</sup>H COSY) (250MHz, CD<sub>3</sub>OD,  $\delta$ ): 0.87 (3H,t), 1.25 (br. s), 1.65 (2H, m), 2.06 (m, =C-CH<sub>2</sub>), 2.42 (2H, t,  $J=7.4$  Hz), 2.96 (1H, dd,  $J=9.4$  Hz, 1-H), 3.13 (1H, d,  $J=9.6$  Hz, 4'-H), 3.43 (1H, m, 1-H), 3.47 (1H, dd,  $J=9.6, 3.1$  Hz, 2'-H), 3.74 (1H, t,  $J=9.6$  Hz, 3'-H), 4.08 (1H, m, 2-H), 4.12 (1H, m, 5'-H), 4.15 (2H, m, 3-H), 4.23 (2H, d,  $J=7.3$  Hz, 6'-H), 4.83 (1H, d,  $J=3.7$  Hz, 1'-H), 5.38 (t-like,  $J=9.2, 4.4$  Hz, =C-H). <sup>13</sup>C-NMR (62.5 MHz, CD<sub>3</sub>OD,  $\delta$  c): 175.7 (s, 1''-C), 130.8 (d), 34.9, 33.0, 30.7, 30.4, 30.2, 28.1, 25.9, 23.7, 14.5 and for sulfoquinovosyl glyceride moiety of **1** see Table I.

**Alkaline Treatment of SBI**

A solution of 0.17N NaOMe-MeOH(1ml) was added to SBI(1 mg) and the solution was left standing at 20°C for 1 hr. The reaction mixture was neutralized with 2N HCl-MeOH and evaporated, it was partitioned into *n*-hexane-MeOH (3:2) mixture. The *n*-hexane phase containing a mixture of the fatty acid methyl esters was concentrated to 1 ml under reduced pressure and subjected to GC-MS analysis for identification [column PB  $\times$  5, 30M  $\times$  0.022 mm; programmed temperature gas chromatography(33°C,0.6 min; 6°C/min;250°C,20 min); carrier gas, N<sub>2</sub> at a flow rate of 12 ml/min]. The  $t_R$  (min) = a 27.00, b 28.87, c 30.38, d 30.87, e 33.63, f 33.75, g 34.08, h 37.21; a: b: c: d: e: f: g: h = 17:1.5:19:153:1:19:1:2 (see Fig. 1).

**Acknowledgement**

This research program was supported by National Natural Science Foundation of China. No: 39370835

**References**

- [1] Cui, Z., Li, Y. S., Zhao, W. R. and Lu, B. R. (1995). *Chinese Pharm Journal*, **30**, 459-460.
- [2] Cui, Z., Li, Y. S., Zhao, W. R., Ding, W. J., Dong, Y., Liu, D. C. and Chen, H. O. (1997). *Chinese Journal of Marine Drugs*, **16**, 5-8.
- [3] Liu, H. B., Cui, Z., Li, Y. S., Yin, J., Dong, Y., Ding, W. J., Liu, T. and Lu, B. R. (1998). *Chinese Pharm Journal*, **33**, 464-466.
- [4] Liu, H. B., Cui, Z. and Li, Y. S. (1999). *Chinese. Pharm. Journal*, **34**, 549.

- [5] Kitagawa, I., Hamamoto, Y. and Kobayashi, M. (1979). *Chem. Pharm. Bull.* **27**, 1934–1937.
- [6] Son, B. W. (1990). *Phytochemistry*, **29**, 307–309.
- [7] Kikuchi, H., Tsukitani, Y., Manda, T. (1982). *Chem. Pharm. Bull.* **30**, 3544–3547.
- [8] Che, C. T. (1991). *Drug Dev. Res.*, **23**, 201–208.